Prime Medicine, Inc.
Prime Medicine, Inc.（PRME）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · PRME · 截至 2025年9月30日
股东结构概览
179
机构持有人数
▲ 51 vs Q2
$511.62M
机构持仓总市值
▲ $366.48M vs Q2
180.62M
总流通股
freeFloat 32.76%
92.36M
13F 申报持股数
▲ 33.62M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
PRME 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
ALPHABET INC. biological products, (no diagnostic substances) | 16.56M | 12.82% | 12.82% | $91.76B | Nov 7, 2025 | ▲ 1.50M |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 9.22M | 7.13% | 7.13% | $51.06B | Nov 14, 2025 | ▲ 2.73M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 5.65M | 4.37% | 4.37% | $31.31B | Nov 12, 2025 | ▲ 1.17M |
ARK INVESTMENT MANAGEMENT LLC biological products, (no diagnostic substances) | 5.48M | 4.24% | 4.24% | $30.35B | Nov 12, 2025 | ▲ 3.16M |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 4.92M | 3.81% | 3.81% | $27.27B | Nov 7, 2025 | ▲ 1.29M |
FARALLON CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 4.75M | 3.68% | 3.68% | $26.32B | Feb 17, 2026 | ▲ 4.00M |
SUMITOMO MITSUI TRUST HOLDINGS, INC. biological products, (no diagnostic substances) | 3.63M | 2.81% | 2.81% | $20.11B | Oct 27, 2025 | ▲ 2.04M |
NIKKO ASSET MANAGEMENT AMERICAS, INC. biological products, (no diagnostic substances) | 3.63M | 2.81% | 2.81% | $20.04B | Nov 12, 2025 | ▲ 2.04M |
CASDIN CAPITAL, LLC biological products, (no diagnostic substances) | 3.17M | 2.45% | 2.45% | $17.55B | Nov 14, 2025 | ▲ 1.60M |
WOODLINE PARTNERS LP biological products, (no diagnostic substances) | 3.00M | 2.32% | 2.32% | $16.63B | Nov 14, 2025 | NEW |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
32
增持
+26.88M 股10
新建仓
首次建仓4
减持
−1.29M 股0
清仓
完全退出净股数变化（前50家）
+25.59M
+26.88M / −1.29M
净新增持仓人
+38
新建 10 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
PRME 内幕交易记录
数据来源：SEC Form 4
1
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Makhni Svetlana Ni Chief Financial Officer | Apr 16, 2026 | Award | 800,000 | $3.67 | $2.94M | 800.0K | Form 4 ↗ |
Reine Allan Chief Executive Officer | Feb 26, 2026 | Award | 1,300,000 | $4.38 | $5.69M | 1.30M | Form 4 ↗ |
LEE ANN L. Chief Technical Officer | Feb 23, 2026 | Award | 375,000 | $3.34 | $1.25M | 375.0K | Form 4 ↗ |
Alenson Carman See Remarks | Feb 23, 2026 | Award | 140,000 | $3.34 | $467.6K | 140.0K | Form 4 ↗ |
LEE ANN L. Chief Technical Officer | Aug 1, 2025 | Award | 180,995 | $4.04 | $731.2K | 181.0K | Form 4 ↗ |
LEE ANN L. Chief Technical Officer | Aug 1, 2025 | D-Return | 180,995 | $12.30 | $2.23M | 0 | Form 4 ↗ |
LEE ANN L. Chief Technical Officer | Aug 1, 2025 | D-Return | 180,995 | $8.49 | $1.54M | 0 | Form 4 ↗ |
Schenkein David P director | Aug 1, 2025 | Award | 45,000 | $4.04 | $181.8K | 45.0K | Form 4 ↗ |
Schenkein David P director | Aug 1, 2025 | Award | 39,062 | $4.04 | $157.8K | 39.1K | Form 4 ↗ |
Schenkein David P director | Aug 1, 2025 | D-Return | 45,000 | $7.68 | $345.6K | 0 | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Prime Medicine, Inc.（PRME）主要由机构投资者持有，机构持股比例约为 51.1%。公司内部人员持股约 67.24%，散户及公众持股约占剩余的 0.00%。
Prime Medicine, Inc. 最大机构股东为 ALPHABET INC.，截至 September 30, 2025 持有约 16.56 million 股，占总流通股的 12.82%。
目前共有 179 家机构持有 PRME 股票，合计持仓市值约 $511,622,160，数据来源为最新 SEC 13F 申报。
常见问题
PRME ownershipPrime Medicine, Inc.（PRME）主要由机构投资者持有，机构持股约 51.1%。最大股东为 ALPHABET INC.，持股比例 12.82%。内部人员持股约 67.24%。数据来源 SEC Form 13F，截至 September 30, 2025。